MuseChem is somewhere for you to buy chemicals online


First penicillin-binding protein occupancy patterns for 15 β-lactams and β-lactamase inhibitors in Mycobacterium abscessus

Alaa R. M. Sayed, Nirav R. Shah, Kari B. Basso, Manasi Kamat, Yuanyuan Jiao, Bartolome Moya, Dhruvitkumar S. Sutaria, Yinzhi Lang, Xun Tao, Weiguo Liu, Eunjeong Shin, Jieqiang Zhou, Carolin Werkman, Arnold Louie, George L. Drusano, Jürgen B. Bulit

Anticirobial Agents and Chemotherapy;   Accepted Manuscript Posted Online 26 October 2020

Mycobacterium abscessus (Mab) causes serious infections that often require over 18 months of antibiotic combination therapy. There is no standard regimen for the treatment of Mab infections and the multitude of combinations that have been used clinically have had low success rates and high rates for toxicities. With β-lactam antibiotics being safe, double β-lactam and β-lactam/β-lactamase inhibitor combinations are of interest for improving treatment of Mab infections and minimizing toxicity. However, a mechanistic approach for building these combinations is lacking since little is known about which penicillin-binding protein (PBP) target receptors are inactivated by different β-lactams in Mab. We determined the preferred PBP targets of 13 β-lactams and two β-lactamase inhibitors in two Mab strains and identified PBP sequences by proteomics. The Bocillin FL binding assay was used to determine the β-lactam concentrations (IC50) that half-maximally inhibited Bocillin binding. Principal component analysis identified four clusters of PBP occupancy patterns. Carbapenems inactivated all PBPs at low concentrations (0.016-0.5mg/L; cluster 1). Cephalosporins (cluster 2) inactivated PonA2, PonA1, and PbpA at low (0.031-1mg/L; ceftriaxone and cefotaxime) or intermediate concentrations (0.35-16mg/L; ceftazidime and cefoxitin). Sulbactam, aztreonam, carumonam, mecillinam and avibactam (cluster 3) inactivated the same PBPs as cephalosporins, but required higher concentrations. Other penicillins (cluster 4) specifically targeted PbpA at 2-16mg/L. Carbapenems, ceftriaxone and cefotaxime were the most promising β-lactams since they inactivated most or all PBPs at clinically relevant concentrations. These first PBP occupancy patterns in Mab provide a mechanistic foundation for selecting and optimizing safe and effective combination therapies with β-lactams.

Products Used in this Publication

Catalog NumberCASProduct NamePrice
I003307 1192491-61-4 Avibactam sodium Inquiry
A000865 34642-77-8 Amoxicillin Sodium Inquiry

Related Products

Catalog NumberCASProduct NamePrice
I038808 2621928-55-8 MRTX1133 Inquiry
I038807 68341-12-8 CuATSP Inquiry
I021757 129277-38-9 Lobetyolin Inquiry
© 2017-2022 MuseChem Chemicals All Rights Reserved.